NO175592C - Analogifremgangsmåte for fremstilling av terapeutisk aktive xantiner - Google Patents

Analogifremgangsmåte for fremstilling av terapeutisk aktive xantiner

Info

Publication number: NO175592C
Authority: NO; Norway
Prior art keywords: formula; disorders; xanthines; preparation; therapeutically active
Prior art date: 1989-03-23

Application number

NO901300A

Other languages

English (en)

Norwegian (no)

Other versions

NO175592B (no

NO901300D0 (no

NO901300L (no

Inventor

Harald Maschler

Barbara Ann Spicer

Harry Smith

Original Assignee

Beecham Wuelfing Gmbh & Co Kg

Beecham Group Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-03-23

Filing date

1990-03-21

Publication date

1994-11-02

1990-03-21 Application filed by Beecham Wuelfing Gmbh & Co Kg, Beecham Group Plc filed Critical Beecham Wuelfing Gmbh & Co Kg

1990-03-21 Publication of NO901300D0 publication Critical patent/NO901300D0/no

1990-09-24 Publication of NO901300L publication Critical patent/NO901300L/no

1994-07-25 Publication of NO175592B publication Critical patent/NO175592B/no

1994-11-02 Publication of NO175592C publication Critical patent/NO175592C/no

Links

LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title 1
229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
125000000217 alkyl group Chemical group 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
230000002490 cerebral effect Effects 0.000 abstract 1
208000026106 cerebrovascular disease Diseases 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
231100000252 nontoxic Toxicity 0.000 abstract 1
230000003000 nontoxic effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Saccharide Compounds (AREA)
Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO901300A 1989-03-23 1990-03-21 Analogifremgangsmåte for fremstilling av terapeutisk aktive xantiner NO175592C (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB898906792A GB8906792D0 (en)	1989-03-23	1989-03-23	Treatment and compounds

Publications (4)

Publication Number	Publication Date
NO901300D0 NO901300D0 (no)	1990-03-21
NO901300L NO901300L (no)	1990-09-24
NO175592B NO175592B (no)	1994-07-25
NO175592C true NO175592C (no)	1994-11-02

Family

ID=10653940

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO901300A NO175592C (no)	1989-03-23	1990-03-21	Analogifremgangsmåte for fremstilling av terapeutisk aktive xantiner

Country Status (27)

Country	Link
US (4)	US5734051A (fr)
EP (2)	EP0389282B1 (fr)
JP (1)	JP2510889B2 (fr)
KR (1)	KR0160768B1 (fr)
CN (1)	CN1031641C (fr)
AT (1)	ATE213498T1 (fr)
AU (1)	AU629315B2 (fr)
CA (1)	CA2012686C (fr)
CZ (1)	CZ391891A3 (fr)
DE (1)	DE69033915T2 (fr)
DK (1)	DK0389282T3 (fr)
ES (1)	ES2173074T3 (fr)
FI (1)	FI95033C (fr)
GB (1)	GB8906792D0 (fr)
HK (1)	HK1040392A1 (fr)
HU (1)	HU207081B (fr)
IL (1)	IL93832A (fr)
MA (1)	MA21800A1 (fr)
MY (1)	MY109737A (fr)
NO (1)	NO175592C (fr)
NZ (1)	NZ233021A (fr)
PL (1)	PL164811B1 (fr)
PT (1)	PT93527B (fr)
SA (1)	SA90100215B1 (fr)
SK (1)	SK391891A3 (fr)
ZA (1)	ZA902170B (fr)
ZW (1)	ZW3690A1 (fr)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5021422A (en) *	1989-06-08	1991-06-04	Senetek Plc	Method and composition for treating hyperproliferative skin diseases using 6-aminopurine cytokinins
GB9020921D0 (en) *	1990-09-26	1990-11-07	Beecham Group Plc	Novel compounds
GB9020959D0 (en) *	1990-09-26	1990-11-07	Beecham Group Plc	Novel compounds
IL100088A (en) *	1990-11-21	1995-07-31	Smithkline Beecham Corp	FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8
ES2148170T3 (es) *	1990-12-21	2000-10-16	Beecham Group Plc	Derivados de xantina.
EP0593567B1 (fr)	1991-07-05	1996-08-28	Byk Gulden Lomberg Chemische Fabrik Gmbh	Utilisation de pyridazines substituees pour le traitement de dermatoses
WO1993016699A1 (fr) *	1992-02-21	1993-09-02	Smithkline Beecham Corporation	Inhibiteurs du facteur necrotique tumoral
US5342841A (en) *	1992-03-12	1994-08-30	Kyowa Hakko Kogyo Co., Ltd.	Xanthine derivatives
CA2093403C (fr) *	1992-04-08	1999-08-10	Fumio Suzuki	Agent de traitement de la maladie de parkinson
GB9210839D0 (en) *	1992-05-21	1992-07-08	Smithkline Beecham Plc	Novel compounds
GB9215633D0 (en) *	1992-07-23	1992-09-09	Smithkline Beecham Plc	Novel treatment
US6469017B1 (en) *	1998-01-16	2002-10-22	Cell Therapeutics, Inc.	Method of inhibiting interleukin-12 signaling
US6693105B1 (en)	1992-11-16	2004-02-17	Cell Therapeutics, Inc.	Hydroxyl-containing compounds
GB9312853D0 (en)	1993-06-22	1993-08-04	Euro Celtique Sa	Chemical compounds
US6878715B1 (en) *	1994-02-18	2005-04-12	Cell Therapeutics, Inc.	Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
US5646156A (en) *	1994-04-25	1997-07-08	Merck & Co., Inc.	Inhibition of eosinophil activation through A3 adenosine receptor antagonism
US5591776A (en)	1994-06-24	1997-01-07	Euro-Celtique, S.A.	Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5922751A (en)	1994-06-24	1999-07-13	Euro-Celtique, S.A.	Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
DE69531506T2 (de)	1994-12-13	2004-06-24	Euroceltique S.A.	Arylthioxanthine
EP0799040B1 (fr)	1994-12-13	2003-08-20	Euroceltique S.A.	Thioxanthines trisubstituees
AU692104B2 (en) *	1995-05-19	1998-05-28	Darwin Discovery Limited	Xanthines and their therapeutic use
US6166041A (en)	1995-10-11	2000-12-26	Euro-Celtique, S.A.	2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en)	1996-04-10	2000-06-13	Euro-Celtique S.A.	6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
US5864037A (en)	1996-06-06	1999-01-26	Euro-Celtique, S.A.	Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US5958926A (en) *	1996-11-01	1999-09-28	Nitromed, Inc.	Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
GB9623859D0 (en) *	1996-11-15	1997-01-08	Chiroscience Ltd	Novel compounds
GB9703044D0 (en)	1997-02-14	1997-04-02	Glaxo Group Ltd	Phenyl xanthine esters and amides
DE69834500T2 (de) *	1997-09-05	2007-05-03	Kyowa Hakko Kogyo Co., Ltd.	Xanthinderivative zur behandlung von hirnischämie
AR015190A1 (es)	1997-10-23	2001-04-18	Smithkline Beecham Corp	Un polimorfo cristalino de 1,3-diciclopropilmetil-8-aminoxantina, procedimiento para su preparacion, composiciones farmaceuticas que lo contienen y su usopara la manufactura de un medicamento
GB9817623D0 (en)	1998-08-13	1998-10-07	Glaxo Group Ltd	Pharmaceutical compounds
CA2715683A1 (fr)	1999-08-21	2001-03-01	Nycomed Gmbh	Combinaison synergiste
CA2402384A1 (fr) *	2000-03-16	2001-09-20	Inflazyme Pharmaceuticals Ltd.	Inhibiteurs benzyles de pde4
US6821978B2 (en) *	2000-09-19	2004-11-23	Schering Corporation	Xanthine phosphodiesterase V inhibitors
US6586429B2 (en)	2000-11-29	2003-07-01	Cell Therapeutics, Inc.	Tricyclic fused xanthine compounds and their uses
EP1368349B1 (fr) *	2001-02-24	2007-02-14	Boehringer Ingelheim Pharma GmbH & Co.KG	Derives xanthine, fabrication et utilisations en tant qu'agents pharmaceutiques
WO2002089736A2 (fr) *	2001-05-08	2002-11-14	Blanchette Rockefeller Neurosciences Institute	Antagonistes du recepteur de l'adenosine a1 permettant de traiter des troubles de la memoire et de l'apprentissage induits par une hypoxie
US6825180B2 (en)	2001-05-18	2004-11-30	Cell Therapeutics, Inc.	Pyridopyrimidine compounds and their uses
WO2003015789A2 (fr) *	2001-08-15	2003-02-27	Leo Pharma A/S	Composition pharmaceutique pour application cutanee
ATE395349T1 (de)	2001-08-28	2008-05-15	Schering Corp	Polycyclische guanin phosphodiesterase inhibitoren
CA2465893A1 (fr)	2001-11-09	2003-05-22	Schering Corporation	Inhibiteurs de la phosphodiesterase v de derives polycycliques de guanine
US20030175314A1 (en) *	2001-11-19	2003-09-18	Didriksen Erik Johannes	Pharmaceutical composition for dermal application
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
US7153824B2 (en)	2003-04-01	2006-12-26	Applied Research Systems Ars Holding N.V.	Inhibitors of phosphodiesterases in infertility
WO2005012303A1 (fr) *	2003-07-31	2005-02-10	Schering Corporation	Metabolite de l'inhibiteur de xanthine phosphodiesterase 5 et derives de ce metabolite, utiles dans le traitement de la dyserection
EP1709966A4 (fr) *	2003-12-09	2009-04-29		Agent preventif et/ou therapeutique pour un dysfonctionnement cerebral severe
PL1781657T3 (pl)	2004-02-14	2013-08-30	Glaxosmithkline Ip Dev Ltd	Leki o aktywności wobec receptora HM74A
RU2395511C2 (ru) *	2004-02-14	2010-07-27	Смитклайн Бичам Корпорейшн	Новые соединения
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004030502A1 (de)	2004-06-24	2006-01-12	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
ES2401128T3 (es)	2005-08-10	2013-04-17	Glaxosmithkline Llc	Derivados de xantina como agonistas selectivos de HM74A
EP2001874A4 (fr) *	2006-03-21	2010-04-07	Reddys Lab Ltd Dr	Polymorphes de docétaxel et procédés
EP1852108A1 (fr)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Compositions d'inhibiteurs de la DPP IV
EP2540725A1 (fr)	2006-05-04	2013-01-02	Boehringer Ingelheim International GmbH	Polymorphes de 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
JP2010500326A (ja)	2006-08-08	2010-01-07	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糖尿病の治療のためのｄｐｐ−ｉｖ阻害剤としてのピロロ［３，２−ｄ］ピリミジン
MX354786B (es)	2007-06-04	2018-03-21	Synergy Pharmaceuticals Inc	Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US8871751B2 (en) *	2008-01-18	2014-10-28	The Board Of Trustees Of The University Of Illinois	Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
ES2522968T3 (es)	2008-06-04	2014-11-19	Synergy Pharmaceuticals Inc.	Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en)	2008-07-16	2015-02-19	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN102149407A (zh)	2008-09-10	2011-08-10	贝林格尔.英格海姆国际有限公司	治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh)	2008-12-23	2011-11-23	贝林格尔.英格海姆国际有限公司	有机化合物的盐形式
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
KR20240090632A (ko)	2009-11-27	2024-06-21	베링거 인겔하임 인터내셔날 게엠베하	리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh)	2010-05-05	2013-02-27	贝林格尔.英格海姆国际有限公司	组合疗法
WO2011161161A1 (fr)	2010-06-24	2011-12-29	Boehringer Ingelheim International Gmbh	Thérapie du diabète
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
DK2681236T3 (en)	2011-03-01	2018-04-16	Synergy Pharmaceuticals Inc	PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
US8883800B2 (en)	2011-07-15	2014-11-11	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
JP6218811B2 (ja)	2012-05-14	2017-10-25	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja)	2012-05-14	2017-11-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (fr)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
WO2014131024A2 (fr)	2013-02-25	2014-08-28	Synergy Pharmaceuticals Inc.	Agonistes de la guanylate cyclase et applications associées
AU2014235215A1 (en)	2013-03-15	2015-10-01	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
AU2014235209B2 (en)	2013-03-15	2018-06-14	Bausch Health Ireland Limited	Guanylate cyclase receptor agonists combined with other drugs
BR112015030326A2 (pt)	2013-06-05	2017-08-29	Synergy Pharmaceuticals Inc	Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
AU2014305843B2 (en)	2013-08-09	2019-08-29	Ardelyx, Inc.	Compounds and methods for inhibiting phosphate transport
EP3110449B1 (fr)	2014-02-28	2023-06-28	Boehringer Ingelheim International GmbH	Utilisation médicale d'un inhibiteur de dpp-4
EP3251675B1 (fr)	2015-01-30	2021-04-21	Shanton Pharma Pte. Ltd.	Prévention ou traitement de maladie de goutte ou d'acide urique
BR112017021386A2 (pt)	2015-04-08	2018-07-03	Lewis And Clark Pharmaceuticals, Inc.	carbamatos de alquinila com xantina substituída/carbamatos reversos como antagonistas de a2b.
EP3165224A1 (fr)	2015-11-09	2017-05-10	Albert-Ludwigs-Universität Freiburg	Utilisation d'inhibiteurs de pde4 pour la prophylaxie et/ou la thérapie de la dyslipoproteinémie et des troubles apparentés
WO2017089347A1 (fr)	2015-11-25	2017-06-01	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Procédés et compositions pharmaceutiques pour le traitement de mélanomes résistant aux inhibiteurs de braf
CN109310697A (zh)	2016-06-10	2019-02-05	勃林格殷格翰国际有限公司	利格列汀和二甲双胍的组合
EP4706758A3 (fr)	2019-05-21	2026-05-06	Ardelyx, Inc.	Procedes d'inhibition du transport de phosphate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US757328A (en) *	1903-02-07	1904-04-12	Boehringer & Soehne	Art of preparing xanthin derivatives.
US2517410A (en) *	1947-08-15	1950-08-01	Searle & Co	Hydroxy alkyl xanthines and the production thereof
US2534813A (en) *	1950-01-21	1950-12-19	Searle & Co	8-haloxanthine salts of cyclic-aminoalkyl benzohydryl ethers and the production thereof
US4120947A (en) *	1976-03-31	1978-10-17	Cooper Laboratories, Inc.	Xanthine compounds and method of treating bronchospastic and allergic diseases
CH654008A5 (fr) *	1979-05-22	1986-01-31	Nestle Sa	Procede de preparation de 1,3,7-trialkylxanthines.
IT1200944B (it) *	1982-08-10	1989-01-27	Malesci Sas	Derivati xantinici,procedimento per la loro preparazione,composizione farmaceutiche che il contengono e loro impiego terapeutico
US4593095A (en) *	1983-02-18	1986-06-03	The Johns Hopkins University	Xanthine derivatives
US4567183A (en) *	1983-03-11	1986-01-28	Analgesic Associates	Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
US4558051A (en) *	1983-10-11	1985-12-10	Richardson-Vicks, Inc.	Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
DE3406533A1 (de) *	1984-02-23	1985-08-29	Boehringer Mannheim Gmbh, 6800 Mannheim	Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
US4666914A (en) *	1985-05-13	1987-05-19	Schering Corporation	Anti-inflammatory and anti-allergic substituted-2,3-dihydro-6-(hydroxy)pyrimido[2,1-f]-purine-4,8(1H,9H)-diones
GB8610136D0 (en) *	1986-04-25	1986-05-29	Wellcome Found	Compounds
GB8621869D0 (en) *	1986-09-11	1986-10-15	Beecham Group Plc	Treatment
PT86427B (pt)	1986-12-22	1990-11-20	Zambeletti Spa L	Processo para a preparacao de derivados de piperidina
IT1197516B (it) *	1986-12-24	1988-11-30	Abc Ist Biolog Chem Spa	Derivati teofillinmetilanici e teofillinmetilditianici procedimento per la loro preparazione e composizioni farmaceutiche che li comprendono

1989
- 1989-03-23 GB GB898906792A patent/GB8906792D0/en active Pending
1990
- 1990-03-20 MA MA22044A patent/MA21800A1/fr unknown
- 1990-03-21 NO NO901300A patent/NO175592C/no unknown
- 1990-03-21 PT PT93527A patent/PT93527B/pt not_active IP Right Cessation
- 1990-03-21 NZ NZ233021A patent/NZ233021A/en unknown
- 1990-03-21 AU AU52083/90A patent/AU629315B2/en not_active Ceased
- 1990-03-21 IL IL9383290A patent/IL93832A/en unknown
- 1990-03-21 ZA ZA902170A patent/ZA902170B/xx unknown
- 1990-03-21 CA CA002012686A patent/CA2012686C/fr not_active Expired - Fee Related
- 1990-03-22 AT AT90303093T patent/ATE213498T1/de not_active IP Right Cessation
- 1990-03-22 EP EP90303093A patent/EP0389282B1/fr not_active Expired - Lifetime
- 1990-03-22 KR KR1019900003902A patent/KR0160768B1/ko not_active Expired - Fee Related
- 1990-03-22 DK DK90303093T patent/DK0389282T3/da active
- 1990-03-22 ES ES90303093T patent/ES2173074T3/es not_active Expired - Lifetime
- 1990-03-22 ZW ZW36/90A patent/ZW3690A1/xx unknown
- 1990-03-22 DE DE69033915T patent/DE69033915T2/de not_active Expired - Fee Related
- 1990-03-22 EP EP00203905A patent/EP1120417A3/fr not_active Withdrawn
- 1990-03-22 FI FI901447A patent/FI95033C/fi not_active IP Right Cessation
- 1990-03-22 HU HU901792A patent/HU207081B/hu not_active IP Right Cessation
- 1990-03-23 CN CN90102240A patent/CN1031641C/zh not_active Expired - Fee Related
- 1990-03-23 MY MYPI90000465A patent/MY109737A/en unknown
- 1990-03-23 JP JP2075359A patent/JP2510889B2/ja not_active Expired - Fee Related
- 1990-03-23 PL PL90284429A patent/PL164811B1/pl not_active IP Right Cessation
- 1990-05-08 SA SA90100215A patent/SA90100215B1/ar unknown
1991
- 1991-12-19 SK SK3918-91A patent/SK391891A3/sk unknown
- 1991-12-19 CZ CS913918A patent/CZ391891A3/cs unknown
1995
- 1995-06-07 US US08/477,157 patent/US5734051A/en not_active Expired - Fee Related
- 1995-06-07 US US08/474,093 patent/US5981535A/en not_active Expired - Fee Related
1998
- 1998-02-17 US US09/024,252 patent/US6180791B1/en not_active Expired - Fee Related
- 1998-12-15 HK HK02100617.1A patent/HK1040392A1/en unknown
2000
- 2000-11-08 US US09/708,338 patent/US6531600B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
SK391891A3 (en)	2000-12-11
EP0389282A2 (fr)	1990-09-26
CN1031641C (zh)	1996-04-24
GB8906792D0 (en)	1989-05-10
CZ391891A3 (en)	1993-11-17
AU5208390A (en)	1990-09-27
HU207081B (en)	1993-03-01
NZ233021A (en)	1993-12-23
AU629315B2 (en)	1992-10-01
MY109737A (en)	1997-05-31
KR900013962A (ko)	1990-10-22
CN1047502A (zh)	1990-12-05
CA2012686A1 (fr)	1990-09-23
PT93527A (pt)	1990-11-07
HK1040392A1 (en)	2002-06-07
NO175592B (no)	1994-07-25
US5734051A (en)	1998-03-31
FI95033B (fi)	1995-08-31
MA21800A1 (fr)	1990-12-31
JP2510889B2 (ja)	1996-06-26
PL164811B1 (pl)	1994-10-31
SA90100215B1 (ar)	2001-10-07
IL93832A (en)	1994-07-31
EP0389282B1 (fr)	2002-02-20
ATE213498T1 (de)	2002-03-15
DE69033915D1 (de)	2002-03-28
JPH02273676A (ja)	1990-11-08
DK0389282T3 (da)	2002-06-03
KR0160768B1 (ko)	1998-12-01
ZW3690A1 (en)	1991-02-06
CA2012686C (fr)	1999-12-07
FI901447A0 (fi)	1990-03-22
NO901300D0 (no)	1990-03-21
US6180791B1 (en)	2001-01-30
HU901792D0 (en)	1990-06-28
IL93832A0 (en)	1990-12-23
HUT54155A (en)	1991-01-28
EP1120417A2 (fr)	2001-08-01
ES2173074T3 (es)	2002-10-16
EP0389282A3 (fr)	1992-07-01
US6531600B1 (en)	2003-03-11
FI95033C (fi)	1995-12-11
EP1120417A3 (fr)	2001-08-08
NO901300L (no)	1990-09-24
DE69033915T2 (de)	2002-10-10
ZA902170B (en)	1991-03-27
PT93527B (pt)	1996-08-30
US5981535A (en)	1999-11-09

Publication	Publication Date	Title
NO175592C (no)	1994-11-02	Analogifremgangsmåte for fremstilling av terapeutisk aktive xantiner
NO174711C (no)	1994-06-22	Analogifremgangsmåte for fremstilling av nye, terapeutisk aktive pyrimidindionderivater
NO913750D0 (no)	1991-09-24	Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske derivater.
ATE79376T1 (de)	1992-08-15	Dithioacetal-verbindungen, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
FR2695387B1 (fr)	1994-10-21	Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
ES2064461T3 (es)	1995-02-01	Derivados de xantina, procedimiento para su preparacion y composicion farmaceutica.
OA09119A (fr)	1991-10-31	Nouveaux céphèmes et leur préparation.
PT87277A (pt)	1988-05-01	Process for the preparation of new bicyclic compounds and pharmaceutical compositions comprising same
FI104071B1 (fi)	1999-11-15	Analogiamenetelmä terapeuttisesti käyttökelpoisten 2,5-dihydro-2,5-diokso-1H-bents[b]atsepiinijohdannaisten valmistamiseksi
DE69129790D1 (de)	1998-08-20	5-Amino-5,6,7,8-Tetrahydrochinoline und verwandte Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
NO173276C (no)	1993-12-01	Analogifremgangsm}te for fremstilling av terapeutisk aktive 1,4-disubstituerte-piperidinylderivater
FI101071B (fi)	1998-04-15	Menetelmä terapeuttisesti käyttökelpoisten 3,4-dihydroisokinoliini-N-o ksidien valmistamiseksi
DE69024154D1 (de)	1996-01-25	Pyrimidoindolderivate und Verfahren zu ihrer Herstellung